Compare AMSC & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMSC | SANA |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | 400 | N/A |
| Industry | Metal Fabrications | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2012 | 2021 |
| Metric | AMSC | SANA |
|---|---|---|
| Price | $39.37 | $3.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $52.00 | $7.60 |
| AVG Volume (30 Days) | 869.1K | ★ 2.3M |
| Earning Date | 05-20-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 143.24 | 17.24 |
| EPS | ★ 3.01 | N/A |
| Revenue | ★ $900,000.00 | N/A |
| Revenue This Year | $34.98 | N/A |
| Revenue Next Year | $21.38 | N/A |
| P/E Ratio | $12.56 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.16 | $1.54 |
| 52 Week High | $70.49 | $6.55 |
| Indicator | AMSC | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 68.41 | 58.35 |
| Support Level | $38.80 | $2.84 |
| Resistance Level | $64.57 | $3.78 |
| Average True Range (ATR) | 2.12 | 0.24 |
| MACD | 0.75 | 0.08 |
| Stochastic Oscillator | 99.65 | 62.68 |
American Superconductor Corp generates the ideas, technologies, and solutions that meet the world's demand for smarter, cleaner, and energy. Through its Windtec Solutions, the company enables manufacturers to launch wind turbines quickly, effectively, and profitably. Through its Gridtec Solutions, the company provides engineering planning services and grid systems that optimize network reliability, efficiency, and performance. The company's segment includes Grid and Wind. It generates maximum revenue from the Grid segment.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.